Search

Displaying results 5241 - 5250 of 10000 in total
  1. Drug

    Laropiprant

    go.drugbank.com/drugs/DB11629
    ApprovedWithdrawn

    Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

  2. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis

  3. Drug

    ND7001

    go.drugbank.com/drugs/DB05142
    Experimental

    ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. … It is a new type of antidepressant drug with anxiolytic activity.

  4. Drug

    Ergosterol

    go.drugbank.com/drugs/DB04038
    ApprovedWithdrawn

    in ERGOCALCIFEROL. … A steroid of interest both because its biosynthesis in FUNGI is a target of ANTIFUNGAL AGENTS, notably AZOLES, and because when it is present in SKIN of animals, ULTRAVIOLET RAYS break a bond to result

  5. Drug

    ABT-560

    go.drugbank.com/drugs/DB06093
    Experimental

    ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.

  6. Drug

    SOT-107

    go.drugbank.com/drugs/DB05337
    Investigational

    SOT-107 is a drug that is a combination of a protein called transferrin and a poison called diphtheria toxin. This drug treat for a type of brain cancer called a high grade glioma brain tumour.

  7. Drug

    Vitespen

    go.drugbank.com/drugs/DB06400
    Investigational

  8. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    [L49266] It was approved alongside [exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients … [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who

  9. Drug

    Darusentan

    go.drugbank.com/drugs/DB04883
    Investigational

    Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.

  10. Drug

    Mevastatin

    go.drugbank.com/drugs/DB06693
    Experimental

    Mevastatin is a pro-drug that is activated by <i>in vivo</i> hydrolysis of the lactone ring. It has served as one of the lead compounds for the development of the synthetic compounds used today. … During a search for antibiotic compounds produced by fungi in 1971, Akira Endo at Sankyo Co. (Japan) discovered a class of compounds that appeared to lower plasma cholesterol levels.